Statute Details
- Title: Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007
- Act Code: HPA2007-S683-2007
- Type: Subsidiary Legislation (SL)
- Authorising Act: Health Products Act 2007 (Act 15 of 2007)
- Enacting Authority: Health Sciences Authority (with Minister for Health approval)
- Commencement: 1 January 2008
- Current Version: Current version as at 27 Mar 2026 (per provided status)
- Key Parts: Part I (Preliminary), Part II (Supply of Cosmetic Products), Part III (Advertisement), Part IV (Additional Duties and Obligations)
- Key Sections (from extract): Section 2 (Definitions), Section 3 (Application)
- Notable Provisions (from table of contents): s 4 (Duty to notify), s 6 (Contents), s 7 (Labelling), s 8 (Misleading labelling), s 9 (Advertisement), s 10 (Records), s 11 (Reporting defects/adverse effects)
- Schedules: First and Second Schedules (repealed); Fourth Schedule (Standard references for cosmetic ingredient nomenclature)
What Is This Legislation About?
The Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007 (“Cosmetic Regulations”) form Singapore’s regulatory framework for cosmetic products, designed to align with the ASEAN Cosmetic Directive. In practical terms, the Regulations set out compliance duties for businesses that supply, advertise, label, and maintain documentation for cosmetic products placed on the Singapore market.
Cosmetics are often perceived as “low risk” compared with medicines. However, cosmetic products can still cause harm—through contamination, unsafe ingredients, or misleading claims that lead consumers to misuse products. The Regulations therefore focus on ensuring that cosmetic products meet defined content and labelling standards, that market entry is notified to the competent authority, and that adverse effects and defects are reported.
Although the extract provided is partial, the structure and headings indicate a comprehensive compliance regime spanning the lifecycle of a cosmetic product in Singapore: from supply notification and ingredient/content requirements, to labelling and advertising controls, and finally to recordkeeping and post-market safety reporting.
What Are the Key Provisions?
1. Definitions and the “cosmetic product” concept (s 2). The Regulations begin by defining “cosmetic product” by reference to the First Schedule to the Health Products Act 2007. This is a critical drafting technique: rather than attempting to define cosmetics exhaustively within the subsidiary legislation, the Regulations incorporate the statutory definition. For practitioners, this means classification disputes often turn on the Health Products Act’s schedule and the factual presentation of the product (e.g., intended use and product description).
2. Scope and exclusions (s 3). Section 3 is particularly important for importers and exporters. The Regulations do not apply to a cosmetic product that is (a) imported into Singapore solely for re-export, or (b) manufactured in Singapore solely for export. This carve-out reflects a policy choice: where the product does not enter the Singapore consumer market, the Singapore compliance regime is not triggered. Lawyers advising cross-border supply chains should therefore map the commercial route carefully—if a product is merely transiting or held for re-export, the exclusion may apply; if it is made “available for sale in Singapore,” the Regulations likely apply.
3. Duty to notify the Authority of supply (s 4). The Regulations impose a duty to notify the Health Sciences Authority (HSA) when cosmetic products are supplied. While the extract does not reproduce the notification mechanics, the heading indicates a formal obligation tied to market placement. In practice, notification requirements are often the gateway compliance step: failure to notify can create regulatory exposure even if the product’s ingredients and labelling are otherwise compliant. Counsel should therefore treat notification as a “front-end” obligation and ensure internal processes capture new SKUs, reformulations, and changes in responsible parties.
4. Contents of cosmetic products (s 6), labelling (s 7), and misleading labelling (s 8). The Regulations address product safety and consumer information through content and labelling controls. Section 6 (“Contents of cosmetic products”) signals that there are rules about what cosmetic products may contain—typically including permitted ingredients, restrictions, and compliance with standards referenced elsewhere in the regulatory framework. Sections 7 and 8 then regulate how products are presented to consumers. Labelling requirements are usually designed to ensure accurate ingredient disclosure, proper identification of the product, and traceability. “Misleading labelling” provisions (s 8) are especially relevant for enforcement: even if an ingredient is permitted, claims or presentation that mislead consumers (for example, implying medical treatment or overstating effects) can breach the Regulations.
5. Advertisement controls (s 9). Cosmetic advertising is regulated to prevent misleading or unsubstantiated claims. For legal teams, this is a key interface between regulatory compliance and marketing law. Counsel should review advertising copy, influencer scripts, and online product pages against the labelling and advertising standards under the Regulations. Where claims are made about performance, safety, or benefits, the legal risk is not limited to the label—advertisements can independently trigger non-compliance.
6. Recordkeeping and post-market safety (ss 10 and 11). The Regulations impose ongoing duties beyond initial market entry. Section 10 requires the maintenance of records of supply. This is vital for traceability: if there is a complaint, defect, or adverse event, the Authority can investigate and identify affected batches or distribution channels. Section 11 requires reporting of defects and adverse effects to the Authority. This is a post-market surveillance mechanism. Practitioners should ensure that companies have a compliant complaint-handling workflow, including internal escalation, documentation, and timely reporting to HSA when adverse effects or defects occur.
How Is This Legislation Structured?
The Cosmetic Regulations are organised into four main Parts, plus schedules:
Part I (Preliminary) contains the citation and commencement provisions, definitions, and application (including the important exclusions for re-export and export-only manufacturing).
Part II (Supply of Cosmetic Products) covers the core market-entry and product compliance obligations. It includes duties to notify the Authority (s 4), product content requirements (s 6), and consumer-facing information rules such as labelling (s 7) and misleading labelling (s 8). Section 5 is shown as deleted in the provided table of contents, indicating amendments over time.
Part III (Advertisement of Cosmetic Products) contains the advertising compliance provision (s 9). This Part is designed to regulate claims made to the public, including through traditional and digital channels.
Part IV (Additional Duties and Obligations) imposes operational compliance duties: maintaining records (s 10) and reporting defects and adverse effects (s 11). These provisions are essential for enforcement and for protecting consumers after products are already on the market.
Schedules include repealed schedules (First and Second) and a Fourth Schedule that provides standard references used for cosmetic ingredient nomenclature. The nomenclature schedule matters for labelling accuracy: ingredient names must be consistent with recognised references to avoid ambiguity and to support enforcement.
Who Does This Legislation Apply To?
The Regulations apply to parties involved in supplying cosmetic products in Singapore. The definition of “person responsible for placing a cosmetic product in the market” is particularly relevant. It is the person in Singapore who is instrumental in causing the cosmetic product to be available for sale in Singapore. This concept is designed to ensure that there is a Singapore-based accountable party, even where the product originates from overseas manufacturers.
Accordingly, the Regulations are likely to apply to importers, local distributors, brand owners, and other Singapore entities that play a substantive role in making the product available for sale. By contrast, the Regulations do not apply where the product is imported solely for re-export or manufactured solely for export (s 3). Lawyers should therefore advise clients to document the commercial intent and actual market route—especially where goods are stored in Singapore, repackaged, or sold through local channels.
Why Is This Legislation Important?
For practitioners, the Cosmetic Regulations are important because they translate the ASEAN alignment objective into enforceable Singapore obligations. They provide a structured compliance regime that covers both pre-market requirements (notification, content, labelling) and post-market responsibilities (records and adverse effect reporting). This makes the Regulations central to regulatory risk management for cosmetic brands and distributors.
From an enforcement perspective, the labelling and misleading labelling provisions (ss 7–8) and the advertising provision (s 9) are likely to be high-impact. Cosmetic enforcement often focuses on consumer harm and deception: claims that imply medical benefits, improper ingredient disclosure, or inaccurate labelling can lead to regulatory action. The recordkeeping and reporting duties (ss 10–11) also support enforcement by enabling traceability and investigation after incidents.
Practically, the Regulations require legal and compliance teams to integrate regulatory review into commercial workflows. Typical “must-do” steps include: (1) confirming whether a product is a “cosmetic product” under the Health Products Act schedule; (2) determining whether the Singapore entity is the “person responsible” for market placement; (3) ensuring notification processes are completed for each relevant product; (4) verifying ingredient and labelling compliance using the standard nomenclature references; and (5) maintaining robust complaint handling and reporting mechanisms for defects and adverse effects.
Related Legislation
- Health Products Act 2007 (Act 15 of 2007) — the authorising Act; provides the statutory framework and defines “cosmetic product” by reference to its First Schedule.
- Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007 — the subsidiary legislation analysed here.
Source Documents
This article provides an overview of the Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.